# Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

> **NCT02743741** · NA · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 195 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Lutetium-177 Octreotate

## Key facts

- **NCT ID:** NCT02743741
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-15
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-12-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743741, "Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02743741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*